Navigation Links
RESOLVE: The National Infertility Association Announces Partnership With CutisPharma
Date:4/14/2009

Sponsorship Focuses on Website Link to Introduce Consumers to Progesterone Compounding Kits

MCLEAN, Va., April 14 /PRNewswire/ -- As the leading voice for women and men facing infertility, RESOLVE: The National Infertility Association (RESOLVE) announces their partnership with Woburn, MA-based CutisPharma, Inc. This relationship will introduce CutisPharma, Inc., makers of progesterone suppository compounding kits for in-pharmacy use, to RESOLVE constituents.

"RESOLVE applauds CutisPharma for their innovativeness in developing a product that may benefit millions of Americans needing progesterone products," said Barbara Collura, RESOLVE's Executive Director. "I look forward to working closely with CutisPharma to assist women and men in their family building journey."

CutisPharma estimates that over 1.5 million progesterone suppository prescriptions for compounding are written in the U.S. annually. CutisPharma's progesterone suppository compounding kits are available in 25mg, 50mg, 100mg, 200mg, and 400mg strengths allowing maximum flexibility for physicians.

"We are pleased to partner with RESOLVE in increasing our product awareness among RESOLVE members, supporters, and healthcare professionals," said Dr. Indu Muni, CEO of CutisPharma. "As the leader in providing family building support and information to the public, RESOLVE is a trusted source. We are pleased to be included as a resource for RESOLVE."

About RESOLVE: The National Infertility Association

Founded in 1974, RESOLVE: The National Infertility Association, headquartered in McLean, VA, is the oldest and largest consumer-based, nonprofit group that provides education, advocacy and compassionate support for those struggling with infertility in the United States. Each year, RESOLVE and its nationwide network of affiliates and chapters handle more than 1.5 million contacts from people seeking information and help. For more information, visit the RESOLVE website at www.resolve.org.

About CutisPharma, Inc.

CutisPharma, Inc. based in Woburn, MA, is a privately held, specialty pharmaceutical company focusing on the development and commercialization of value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 10 million currently compounded prescriptions, by offering FIRST(R) - Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits will be beneficial to all triad participants, namely physicians, pharmacists, and patients. Two U.S. patents have been issued to the Company with several additional patents pending. For more information on CutisPharma please visit our website at www.firstprogesterone.com or www.cutispharma.com.


'/>"/>
SOURCE CutisPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. International study strengthens case for daily calcium pill
2. Yakima Health Care Leader Tapped for Leadership Post at National Association
3. Virginia Tech Report Has National Importance
4. Donate Life America Dispels Myths About Organ & Tissue Donation Among Hispanics During National Hispanic Heritage Month
5. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. National Association of Subrogation Professionals (NASP), the Largest Insurance Subrogation Association in the World - Announced Today that Leslie Wiernik has Joined the Organization as Director of Education
8. 4-Star Gen. Barry McCaffrey, Former U.S. Drug Czar, to Address National Drug Crisis, Keynote Grand Opening of New Allenwood, PA National Model Detox Center
9. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
10. LCA Hails International Investigators Studying Lung Cancer
11. National Patient Safety Foundation Partners with Vocera Communications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 10, 2016 , ... Everseat has joined the award-winning Allscripts ... physicians. The integration will enable Allscripts users to post open appointments to the ... app. , The partnership gives Everseat substantial added power to help Allscripts meet ...
(Date:2/10/2016)... ... 10, 2016 , ... Workrite Ergonomics this week announced the launch of the ... , “Our goal was to develop a product from the ground up that ... ever created.” said Darren Hulsey, Product Manager for Workrite Ergonomics. “The Conform series ...
(Date:2/10/2016)... ... February 10, 2016 , ... Anxiety of older Americans over steep cost increases ... D a decade ago, according to The Senior Citizens League (TSCL). ... are coping with rapidly rising costs. “The implications are chilling, particularly for people ...
(Date:2/10/2016)... ... February 09, 2016 , ... ... Body Specialists are delighted to welcome a new addition to their growing practice. ... Body Specialists as a nurse practitioner performing cosmetic procedures including injectables, ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... It’s that ... Traci Davis, the new president of the Interscholastic Athletic Association of Maryland (IAAM), Hall ... well how quickly fitness goals are cast aside. , That’s why one of her ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... February 9, 2016 ... heute den Abschluss eines Kooperationsvertrags mit 10x ... Lösungen in den Bereichen Next-Generation-Sequencing (NGS), Single-Cell-Biology ... ; Frankfurt Prime Standard: QIA) gab heute ... für die Entwicklung und Förderung umfassender Lösungen ...
(Date:2/9/2016)... Florida , February 9, 2016 ... today announced a collaboration with 10x Genomics to ... (NGS), single-cell biology and bioinformatics. --> ... a collaboration with 10x Genomics to develop and ... biology and bioinformatics. --> QIAGEN N.V. ...
(Date:2/9/2016)... , Feb. 9, 2016 Mast Therapeutics, ... clinical-stage therapies for sickle cell disease and heart failure, today ... and warrants to purchase common stock in an underwritten public ... and there can be no assurance as to whether or ... actual size or terms of the offering.   ...
Breaking Medicine Technology: